(Reuters) - The U.S. Federal Trade Commission has cleared Valeant Pharmaceuticals International Inc’s (VRX.TO) $2.6 billion deal to buy U.S. dermatology rival Medicis Pharmaceutical Corp MRX.N, without conditions, Valeant said on Friday.
The combined company is set to dominate the U.S. dermatology market. Medicis led that market in gross sales in 2011, while Valeant, Canada’s biggest public drugmaker, ranked third, Valeant said when the deal was first announced.
Valeant, on the acquisition trail since its 2010 takeover by Biovail Corp, which assumed the Valeant name, has favored segments where patients often pay out of pocket, such as ophthalmology and dermatology, cutting its exposure to cost-sensitive insurers.
Medicis’ products include Solodyn, a prescription acne tablet, Restylane, an injectable filler, and Dysport, a competitor to Allergan Inc’s (AGN.N) Botox anti-wrinkle treatment. (Reporting by Allison Martell; editing by John Wallace)